A recent release from the European Medicines Agency has recommended the suspension of the weight-reducing drug rimonabant (which was also in trials for the treatment of nicotine dependence) from the market due to the development of undesirable psychiatric side effects, particularly symptoms of depression.1 This decision follows a similar one regarding rimonabant made by the US Food and Drug Administration last year for the same reasons. In November 2008, Sanofi-Aventis announced it was suspending marketing of rimonabant.2 Soon thereafter, Pfizer announced that it was terminating clinical trials with otenabant, a diet drug with a similar mechanism of action.3
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 31
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.